The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 25987375 |
20 |
Discovery of a novel Kv7 channel opener as a treatment for epilepsy. |
Pfizer |
| 23121096 |
86 |
Ion channels as therapeutic targets: a drug discovery perspective. |
Pfizer |
| 20020710 |
30 |
Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain. |
Icagen |
| 22793372 |
66 |
Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor. |
Vanderbilt University Medical Center |
| 24900334 |
89 |
N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. |
TBA |
| 17483457 |
58 |
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. |
Abbott Laboratories |
| 21296466 |
20 |
Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators. |
Hebei Medical University |
| 20855211 |
91 |
Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. |
Abbott Laboratories |
| 12852750 |
2 |
(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
Search and Browse
